The burden of disease in Saudi Arabia 1990–2017: results from the Global Burden of Disease Study 2017

Abstract

Summary Background Availability of data to assess the population health and provision and quality of health care in Saudi Arabia has been lacking. In 2010, Saudi Arabia began a major investment and transformation programme in the health-care sector. Here we assess the impact of this investment era on mortality, health loss, risk factors, and health-care services in the country. Methods We used results of the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2017 to describe the levels and temporal patterns in deaths, health loss, risk factors, and health-care access and quality in the Saudi Arabian population during 1990–2010 (before the health-care investments and reform) and 2010–17 (during health-care investments and reform). We also compared patterns in health outcomes between these periods with those in the north Africa and the Middle East GBD region and the Gulf Cooperation Council countries. Findings Age-standardised mortality in Saudi Arabia decreased from 1990 to 2010 (annualised rate of change of −0·58%), and this decrease was further accelerated from 2010 to 2017 (–2·20%). The north Africa and the Middle East GBD region also had decreases in mortality during these periods, but for 2010–17 the decrease was not as low as in Saudi Arabia (–1·29%). Transport injuries decreased from third ranked cause of disability-adjusted life-years in 2010 to fifth ranked cause in 2017 in Saudi Arabia, below cardiovascular diseases (ranked first) and musculoskeletal disorders (ranked second). Years lived with disability (YLDs) due to mental disorders, substance use disorders, neoplasms, and neurological disorders consistently increased over the periods 1990–2010 and 2010–17. Between 1990 and 2017, attributable YLDs due to metabolic, behavioural, and environmental or occupational risk factors remained almost unchanged in Saudi Arabia, with high body-mass index, high fasting plasma glucose concentration, and drug use increasing across all age groups. Health-care Access and Quality (HAQ) Index levels increased in Saudi Arabia during this period with similar patterns to the rest of the Gulf Cooperation Council countries and the north Africa and the Middle East GBD region. Interpretation Decreases in mortality continued at greater rates in Saudi Arabia during the period of 2010–17 than in 1990–2010. HAQ Index levels have also improved. Public health policy makers in Saudi Arabia need to increase efforts to address preventable risk factors that are major contributors to the burden of ill health and disability. Funding Bill & Melinda Gates Foundation.

<p>Predictors of Mortality in Patients with Chronic Heart Failure: Is Hyponatremia a Useful Clinical Biomarker?</p>

“…4,33 However, a significantly higher prevalence of type 2 DM in our population (71%) was found in comparison to other CHF populations (28%, 17.6%, 42%, 23.7%, and 26.7%). 4,6,9,10,12 Such alarming prevalence, and negative prognostic value in CHF patients, along with BMI and fasting blood glucose as the top two risk factors in Saudi population, 34 dictates more attention and efficient preventive strategies in our patient population. In this study, we excluded patients with other confounding co-morbidities, such as hereditary anemia and nutritional anemia because of the effect of these conditions on survival and clinical outcomes in heart failure.…”

Cardiovascular Disease Risk Prevention Services by Pharmacists in Saudi Arabia: What Do Policymakers and Opinion Leaders Think?

“…Non-communicable diseases (NCDs) now contribute signi cantly to national disease burdens globally [5], and in Saudi Arabia, these account for approximately 73% of total mortality [6,7]. Saudi Arabia has a nationalised healthcare system with government supported care provided through many public health channels with increasing participation of the private sector in recent years [8].…”

“…Amongst NCDs, cardiovascular diseases (CVD) are major causes of death in Saudi Arabia [7]. There is a high and rising prevalence of CVD and metabolic risk factors among the Saudi public [7], which requires serious national investment into CVD risk prevention services at the community level.…”

“…Amongst NCDs, cardiovascular diseases (CVD) are major causes of death in Saudi Arabia [7]. There is a high and rising prevalence of CVD and metabolic risk factors among the Saudi public [7], which requires serious national investment into CVD risk prevention services at the community level. Research from various countries has demonstrated that pharmacists as primary healthcare professionals can play a role in CVD prevention services [12][13][14][15][16].…”

<p>Thirty-Day Mortality After Curative and Palliative Anti-Cancer Treatment: Data Interpretation and Lessons for Clinical Implementation</p>

“…2 The proportion of deaths due to cancer has also increased in the past 20 years, becoming the third leading cause of death in Saudi Arabia. 3 Chemotherapy agents, which have been shown to improve the survival of cancer patients and their symptoms, have been increasing in number over the past few decades. [4][5][6] Caring for patients with cancer is challenging; to improve clinical decision-making, oncologists need to weigh the risks and benefits of anti-cancer treatments and identify factors that could predict treatment-related morbidity or mortality.…”